ExodusPoint Capital Management LP Makes New Investment in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

ExodusPoint Capital Management LP purchased a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the biotechnology company's stock, valued at approximately $480,000.

Several other institutional investors have also made changes to their positions in AUPH. Arrowstreet Capital Limited Partnership bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth $9,662,000. JPMorgan Chase & Co. increased its holdings in Aurinia Pharmaceuticals by 84.4% in the fourth quarter. JPMorgan Chase & Co. now owns 927,298 shares of the biotechnology company's stock worth $8,327,000 after purchasing an additional 424,482 shares in the last quarter. Barclays PLC boosted its holdings in shares of Aurinia Pharmaceuticals by 187.6% during the 3rd quarter. Barclays PLC now owns 219,331 shares of the biotechnology company's stock worth $1,607,000 after buying an additional 143,072 shares in the last quarter. Vanguard Group Inc. boosted its stake in Aurinia Pharmaceuticals by 6.9% during the fourth quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company's stock worth $15,535,000 after acquiring an additional 112,113 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Aurinia Pharmaceuticals by 22.5% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 556,454 shares of the biotechnology company's stock valued at $4,997,000 after purchasing an additional 102,195 shares during the period. 36.83% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Stock Performance

AUPH stock traded up $0.09 on Friday, hitting $7.76. The company had a trading volume of 929,141 shares, compared to its average volume of 1,353,972. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 12-month low of $4.71 and a 12-month high of $10.67. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -51.74 and a beta of 1.20. The stock's 50-day simple moving average is $7.99 and its 200 day simple moving average is $8.10.

Insiders Place Their Bets

In other Aurinia Pharmaceuticals news, COO Matthew Maxwell Donley sold 65,902 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $527,216.00. Following the completion of the sale, the chief operating officer now directly owns 739,456 shares of the company's stock, valued at $5,915,648. The trade was a 8.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Greg Keenan sold 12,239 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $97,912.00. Following the completion of the transaction, the insider now owns 161,789 shares of the company's stock, valued at $1,294,312. This represents a 7.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 343,898 shares of company stock worth $2,753,094 over the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Separately, StockNews.com raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.